Skip to main content
. 2016 Dec 13;9:7503–7513. doi: 10.2147/OTT.S115268

Figure 6.

Figure 6

Progression-free survival based on CTC kinetics and the status of the KRAS mutation.

Notes: Continuous line: patients with wild type KRAS and favorable kinetics (CTC1+ and CTC2−; 14.7 months). Dotted line: patients with mutant KRAS and favorable kinetics (CTC1+ and CTC2−; 5.3 months). Dashed line: patients with wild-type and unfavorable kinetics (CTC1− and CTC2+; 9.4 months). Dashed-dotted line: patients with mutant KRAS and unfavorable kinetics (CTC1− and CTC2+; 2.4 months) (P=0.02).

Abbreviation: CTC, circulating tumor cell.